Meeting
2021 Gastrointestinal Cancers Symposium
Phase II study of anlotinib plus sintlimab as second-line treatment for patients with advanced biliary tract cancers.
Authors
Hong Zong
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Hong Zong , Qian Zhong , Ruihua Zhao , Shuiling Jin , Chuang Zhou , Xiaojian Zhang , Jianxiang Shi , Shishi Qiao , Jinming Han , Miao Jiang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Hepatobiliary Cancer
Track
Hepatobiliary Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
ChiCTR1900022003
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 307)
DOI
10.1200/JCO.2021.39.3_suppl.307
Abstract #
307
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
The safety and efficacy of ivonescimab in combination with chemotherapy as first-line treatment for advanced biliary tract cancer.
First Author: Jieer Ying
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 2, open-label, safety and efficacy study of telotristat ethyl plus first-line chemotherapy in patients with advanced biliary tract cancer.
First Author: Richard D. Kim
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Updated results from the phase II study: Efficacy and safety of anlotinib plus sintilimab as second-line treatment for patients with advanced biliary tract cancers.
First Author: Shuiling Jin
Poster
2022 ASCO Annual Meeting
A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary cancer.
First Author: Jie Shen